Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7332582B2 · kind B2 · utility
78Cited by
8References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 19, 2004 |
| Grant date | Feb 19, 2008 |
| Priority date | — |
| Expiry date | Nov 19, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.